Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone, and welcome to Visigyn's fiscal year-end 2025 corporate update conference call and webcast. Earlier this afternoon, we issued a press release for our fiscal year-end 2025, which ended on March 31st, 2025, providing an overview of our progress across our lead clinical stage neuroscience programs. We encourage you to review the release and the 10-K, which can be found in our website's investor section. Before we begin, please note that we make forward-looking statements regarding our business during today's call based on current expectations and information. These forward-looking statements speak only as of today, except as law requires. We do not assume any duty to update any forward-looking statements made today or in the future. Of course, forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements we may make today. Additional information concerning risks and factors that could affect our business and financial results are included in our fiscal year-end 2025 Form 10-K for the period ending March 31st, 2025, and in future filings we'll make with the SEC from time to time, all of which are available in the investor section of our website and on the SEC's website. Now, with the formalities out of the way, We warmly welcome our stockholders, sell-side analysts, and interested in our program and progress. I'm joined on our call today by Shawn Singh, our President, Chief Executive Officer, and Cindy Anderson, our Chief Financial Officer. Shawn will discuss recent highlights in our lead neuroscience program, and Cindy will discuss our fiscal year-end 2025 financial results. After our prepared remarks, there will be a brief opportunity for ques...